Johnson & Johnson’s experimental coronavirus vaccine entered human trials this month after an early study showed it helped protect a group of primates with a single kill.
According to a study published in the medical journal Nature, all animals that were exposed to the pandemic six weeks after the injection were immune except one, which showed only low levels of the virus. The results forced the healthcare firm to start human trials last week in Belgium and earlier this week in the US
“We are excited to see this preclinical data because it shows our candidates for the SARS-CoV-2 vaccine generated a strong antibody response and provided single-dose protection,” said Paul Stoffels, the chief scientific officer of Johnson & Johnson. “The findings give us confidence as we move forward with the development of our vaccines and the manufacture of top quality in parallel …”;
The company said it is looking to start the final phase of testing in September and that 1,045 people will participate in the trial.
Johnson & Johnson is competing against a number of other companies in the vaccine race, and while other firms have developed faster, Johnson & Johnson’s ability to produce a single-dose immune response could give it an advantage in vaccine design. .
The company did not announce the predicted price for its shot but said it is increasing manufacturing to try to provide more than 1 billion doses to people around the world.